Bausch and Lomb Newswire (Page 5)

Bausch and Lomb Newswire (Page 5)

Comprehensive Real-Time News Feed for Bausch and Lomb. (Page 5)

Results 81 - 100 of 200 in Bausch and Lomb

  1. Dealmaker of the Week: Alison Ressler of Sullivan & CromwellRead the original story w/Photo

    Feb 27, 2015 |

    Alison Ressler, 57, corporate partner in Sullivan & Cromwell's Los Angeles office. Ressler is also a member of the firm's management committee and serves as co-head of the global private equity group.


  2. Compelling Financial Benefit in Valeant's Latest BuyRead the original story

    Feb 27, 2015 | Morningstar

    Valeant Pharmaceuticals into an entirely new therapeutic area, but the deal is very compelling financially. Management expects the deal to increase 2016 earnings per share more than 20%, and we believe this target is obtainable.


  3. Anika Therapeutics' (ANIK) CEO Charles Sherwood on Q4 2014 Results - Earnings Call TranscriptRead the original story w/Photo

    Feb 26, 2015 | Seeking Alpha

    Good day, ladies and gentlemen and welcome to the Anika Therapeutics' Fourth Quarter 2014 Earnings Conference Call. At this time, all participants are in a listen-only mode.


  4. Valeant Pharmaceuticals International's (VRX) CEO Mike Pearson on Q4...Read the original story w/Photo

    Feb 24, 2015 | Seeking Alpha

    ... projected us to deliver organic growth greater than 12%, and we delivered 16% same store organic growth. Bausch and Lomb reported 8% organic growth for the fourth quarter and 11% organic growth for the full year, and we expect B&L to continue to ...


  5. Jim Cramer on Valeant: This Is an Amazing Pharmaceutical FirmRead the original story

    Feb 24, 2015 |

    It's just incredible . And it merits this move. First, there's regular Valeant, the company that's not yet combined with Salix Valeant announced its quarter a day early and I am shocked at how much better it is doing than we thought.


  6. Valeant Pharmaceuticals - Pearson Strikes Again With Salix AcquisitionRead the original story w/Photo

    Feb 24, 2015 | Seeking Alpha

    Valeant lost the battle to acquire Allergan in 2014. In 2015, it strikes its biggest deal ever, announcing the acquisition of Salix Pharmaceuticals.


  7. Valeant makes comeback with $10.1bn Salix acquisitionRead the original story

    Feb 23, 2015 |

    VALEANT Pharmaceuticals International agreed to buy Salix Pharmaceuticals for about $10.1 billion in cash to add gastrointestinal drugs to its stable of offerings. Salix investors would get $158 a share, the companies said on Sunday.


  8. 4 Pictures Every Valeant-Salix Investor Should SeeRead the original story

    Feb 23, 2015 | Benzinga

    ... Salix represents the biggest, by far, of Valeant's completed deals. The second biggest deal was that of Bausch and Lomb, which represents barely three-quarters of what Valeant has agreed to pay for Salix. Salix relies heavily on Xifaxan. This drug ...


  9. Valeant shares jump on news of deal to buy SalixRead the original story

    Feb 23, 2015 | Rochester Business Journal

    Sent sharply higher by Sunday's news that it plans to acquire Salix Pharmaceuticals Ltd., Valeant Pharmaceuticals International Inc. shares on Monday continued to hold ground they gained at the market's opening bell. After opening $16.81 higher than Friday's $173.26 closing price, Valeant shares at one point on Monday reached a 52-week high of $200.76 - nearly 16 percent higher than the previous close.


  10. Valeant Said to Be Buying Drugmaker Salix for $10.1 BillionRead the original story

    Feb 21, 2015 | The Washington Post

    Valeant will pay $158 a share in cash for Salix, the person said, asking not to be identified because the company hasn't announced the deal. Salix shares rose $7.11 to $157.85 on Friday, almost completely eliminating any premium in the purchase price.


  11. Drug Roundup: February 20, 2015Read the original story

    Feb 20, 2015 | Value Line

    There have been several noteworthy developments in the drug space recently, which will likely have a material impact on the companies in this sector and the markets they serve. Companies mentioned in this review include Pfizer Inc. , Hospira Inc. , Valeant Pharmaceuticals , Salix Pharmaceuticals , Actavis plc , and Allergan Inc. .


  12. Actavis Still Eyes - Couple Billion Dollar' Deals After AllerganRead the original story

    Feb 18, 2015 | The Washington Post

    Actavis Plc Chief Executive Officer Brent Saunders is still on the lookout for acquisition targets while his company digests the $66 billion buyout of Allergan Inc., the drug industry's largest deal of 2014. Actavis will take a pause from doing transformational deals that add new therapeutic areas, Saunders said Wednesday in an interview.


  13. What retirement? Boomers keep workingRead the original story w/Photo

    Feb 17, 2015 | USA Today

    George Fraser has had a successful life. At 70, he is a successful author and speaker, he is still writing books and travels to speaking engagements.


  14. Global Regulatory Affairs Expert Daniela Drago, PhD Joins NDA PartnersRead the original story w/Photo

    Feb 16, 2015 | PRWeb

    NDA Partners announced today that Daniela Drago, PhD, former senior regulatory affairs team leader with Bausch & Lomb and currently Director of the Clinical & Translational Research and Regulatory Affairs programs at the School of Medicine and Health Sciences, George Washington University, has joined the firm as a Premier Expert consultant. NDA Partners Premier Experts are top tier consultants who design and implement critical solutions to help clients successfully develop new medical products, pursue optimal regulatory pathways, build companies that are attractive to professional investors, and initiate access to global markets.


  15. Salix, Top Drug Stocks Rally As Merger Mania Heats UpRead the original story w/Photo

    Feb 13, 2015 | Investor's Business Daily

    The stock surged 5% in heavy trade on Feb. 3 amid reports that It rose 4% Thursday as Valeant reportedly secured financing for a potential deal. Shares of Raleigh, N.C.-based Salix added 2% Friday, as Salix has been trying to recover from a 36% plunge the week ended Nov. 7, when the company reported disappointing Q3 results and Chief Financial Officer Adam Derbyshire abruptly resigned.


  16. Valeant Said to Secure Salix Financing, Closing In on OfferRead the original story

    Feb 12, 2015 | The Washington Post

    Valeant's likely to make an offer of more than $150 per share, one of the people said, asking not to be identified discussing private information. Including net debt, Salix is valued at about $10.9 billion.


  17. Expert on poverty describes city's challengeRead the original story w/Photo

    Feb 6, 2015 | Rochester Business Journal

    A half-century after the War on Poverty was launched, some 45 million Americans are living in poverty, and wages for most working people in this country have risen, after inflation, an average of one-fifth of 1 percent annually over the last 40 years. Yet the contention that nothing works is "wrong, wrong, wrong," Peter Edelman told the 525 people who attended "Rochester's Crisis of Poverty," part of the Rochester Business Journal's Power Breakfast series.


  18. Vaccinogen Elects To Board Of DirectorsRead the original story

    Feb 9, 2015 | BioSpace

    He will also chair the company's Compensation Committee in this new role and serve on the company's Audit Committee. "This is an extremely exciting time for Vaccinogen.


  19. Rising Volume of Cataract Surgeries Spurs Demand for Intraocular...Read the original story

    Feb 4, 2015 | PRWeb

    Rising Volume of Cataract Surgeries Spurs Demand for Intraocular Lenses, According to a New Report by Global Industry Analysts, Inc. GIA announces the release of a comprehensive global report on Intraocular Lenses. The global market for Intraocular Lenses is projected to reach US$4.7 billion by 2020, driven by the rising prevalence of cataract among the aging population and strong adoption of premium IOLs.


  20. Valeant Said to Weigh Salix Takeover Amid Pharma Deal DelugeRead the original story

    Feb 3, 2015 | The Washington Post

    The Canadian drugmaker has discussed its interest with advisers, said the people, who asked not to be identified because the talks are private. Salix has a market value of about $9 billion, after its shares rose 5 percent to $140.47 in New York trading.